Edwards Lifesciences (NYSE:EW) Announces Earnings Results

Edwards Lifesciences (NYSE:EW) posted its quarterly earnings results on Wednesday. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06, FiscalAI reports. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same period last year, the business posted $0.67 EPS. The business’s quarterly revenue was up 10.5% on a year-over-year basis.

Here are the key takeaways from Edwards Lifesciences’ conference call:

• Third-quarter sales rose 11.2% to $1.72 billion, and adjusted EPS was $0.80. Edwards raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97–$3.05.
• TAVR sales increased 8.8%, prompting the company to raise its 2026 TAVR growth outlook to 9%–9.5%. Management cited encouraging procedure trends and expects future growth to come more from market expansion than share gains, which have recently plateaued.
• TMTT sales surged 45.6% to $207 million, and Edwards now expects full-year TMTT sales of $780 million–$790 million. Management said its PASCAL, EVOQUE, and SAPIEN M3 portfolio supports a goal of $2 billion in TMTT revenue by 2030.
• New clinical evidence and the updated U.S. TAVR coverage policy may broaden treatment access over time, including for asymptomatic patients; management also sees potential for a future moderate-aortic-stenosis indication. Executives cautioned that adoption and the impact of these catalysts are expected to build gradually.

Edwards Lifesciences Trading Up 4.4%

NYSE:EW opened at $99.39 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The stock has a market capitalization of $57.23 billion, a PE ratio of 57.12, a price-to-earnings-growth ratio of 2.49 and a beta of 0.85. The business’s 50-day simple moving average is $88.48 and its 200-day simple moving average is $85.61. Edwards Lifesciences has a fifty-two week low of $74.66 and a fifty-two week high of $100.25.

Insiders Place Their Bets

In other news, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,045 shares of company stock valued at $451,596 in the last quarter. 0.31% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EW. Jefferies Financial Group raised their price objective on shares of Edwards Lifesciences from $102.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Barclays upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, October 7th. UBS Group restated a “buy” rating and issued a $110.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a research report on Thursday, October 8th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Raymond James Financial upped their target price on shares of Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $104.08.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80, topping the $0.74 consensus, and revenue of $1.72 billion versus expectations of $1.68 billion. Revenue grew year over year, while the company raised its full-year outlook and narrowed its 2026 forecast range. Q3 earnings, revenue and outlook
• Positive Sentiment: Truist Financial upgraded EW from “hold” to “strong-buy,” adding analyst support. Truist upgrade
• Positive Sentiment: Management highlighted strong momentum in its transcatheter mitral and tricuspid therapies business, with TMTT sales up 44%. Separately, trial results for the PASCAL tricuspid repair system showed better outcomes than medical therapy through one year, supporting the product’s potential. Q3 results and TMTT growth PASCAL trial results
• Negative Sentiment: CEO commentary acknowledged that more TAVR competition is coming, which could pressure Edwards’ position in a key market. RBC also said the Progress trial data is unlikely to meaningfully expand the transcatheter market, limiting the potential upside from that study. TAVR competition RBC assessment of Progress trial

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.